ABL Diagnostics has secured a raised target price of €8.7 from Invest Securities, reflecting strong upside potential based on an accelerated growth trajectory starting in 2026. The analyst reiterated a 'Buy' recommendation, upgrading the target from the previous €8.4 following the company's communication of its financial roadmap. The revised valuation incorporates the ramp-up of growth drivers, an expected improvement in the profitability profile, and the increased contribution of strategic partnerships.

2026 Growth Trajectory

ABL Diagnostics has outlined an ambitious annual trajectory for 2026, targeting revenue of €12.2 million. This represents an increase of 76.5% compared to 2025. The momentum is supported by the recurrence of historical activities in HIV genotyping and software, alongside the ramp-up of new activities integrated in 2025, whose contribution is expected to grow by 93%.

Segment Performance

The growth model is balanced across several engines, with significant variations in expected performance:

Specifically, the kits and reagents segment is driven by HIV growth of 132% and the UltraGene range, which is expected to surge by 353%. This multi-segment positioning is designed to strengthen the visibility and resilience of the business model.

Strategic Catalysts

Invest Securities highlighted several key value creation factors, including a proprietary offering covering tests, software, and services. The company utilizes an 'agnostic platform' approach compatible with major sequencing equipment to limit adoption barriers. New solutions such as HybridChek are expanding the scope of application, while structuring strategic partnerships includes a multi-year contract potentially reaching ~€2.7 million.

Profitability Outlook

The ramp-up in volumes and economies of scale is expected to result in a significant improvement in margins, with increases anticipated in both EBITDA and net income over the period. Despite a constrained in vitro diagnostic market environment, ABL Diagnostics' value proposition is considered sufficiently competitive to support market share gains.

ABL Diagnostics and CDL Pharma have secured a multi-year contract with a European pharmaceutical company for services related to neurodegenerative diseases, potentially worth up to €2.7 million through 2031. The agreement, signed by ABL Diagnostics for services operated by CDL Pharma, includes an initial payment exceeding €100,000 and is part of an international clinical program involving 30 centers across 11 countries in North America, Europe, and Asia.

The contract enhances the visibility of future revenue over multiple financial years and underscores the group's capability to support global multicenter studies. Revenue will be recognized progressively based on service performance and remains contingent on the effective progress of the clinical program. The partnership illustrates the progressive development of value-added services in international clinical research.

Scope of Services

Under the agreement, CDL Pharma will deliver specialized services including the operational management of international clinical trials, logistics and transportation of biological samples, design and management of sampling kits, cryogenic storage, and biomarker analysis. ABL Diagnostics acts as the distributor of these services to the end customer.

Contract Details

Mohamed Errafyqy, Sales and Operations Manager at ABL Diagnostics, commented that the contract illustrates the company's ability to support complex international clinical programs and deliver integrated service offerings. The neurodegenerative diseases market is supported by structural trends such as aging populations and new therapeutic approaches, with industry reports suggesting the market could reach approximately USD 88 billion by 2030–2031. However, these estimates are based on uncertain growth assumptions and do not constitute a prediction of actual market developments or ABL Diagnostics' potential share.